
Boltz
AI that designs the molecules of tomorrow. Scientists at the world’s leading pharma and biotech companies use Boltz to design better molecules with fewer
BioTech
Built from public sources. Run Boltz? Claim this page with your @boltz.com email.
Overview
In the news · Nov 20, 2026Boltz (London, AI drug discovery): $110M Series A, led by Bessemer Venture Partners. The company emerged from stealth less than a year ago. Read the funding digest
About
AI models for designing molecules and proteins. Used by scientists at pharma and biotech companies.
Boltz provides AI models and infrastructure for molecular design used by scientists at leading pharma and biotech companies. The platform enables researchers to design better molecules and proteins with fewer experiments through state-of-the-art AI models and fast inference capabilities.
Problem & Solution
The problem
Drug discovery requires extensive experimentation to design effective molecules and proteins, which is time-consuming and costly.
The solution
Boltz offers frontier AI models and scalable infrastructure that enable scientists to design and optimize small molecules and biologics in minutes through an intuitive interface or API integration.
More from the same digest
- Humyn Labs
- MistralFrontier open-weight models you own and control. Customize with Forge, deploy with Studio, run on-prem, your VPC, or our cloud.
- InPrime Finserv
Gathered from the news article and boltz.com. Not edited by Boltz yet.
Run Boltz? Make this page yours.
Claim it with your @boltz.com email, fix what we got wrong, and share one clean link with investors and customers.
startupcorners